Nature Reviews Cardiology最新文献

Fishing for answers: omega-3 fatty acids and cardiovascular health. 寻找答案：omega-3脂肪酸和心血管健康。

IF 50.2 1区医学

Nature Reviews Cardiology Pub Date : 2026-09-03 DOI: 10.1038/s41569-026-01347-y

Ludmila Caceva

引用次数: 0

The role of hypoxia-inducible factors in myocardial ischaemia-reperfusion injury and cardioprotection. 缺氧诱导因子在心肌缺血再灌注损伤及心脏保护中的作用。

IF 50.2 1区医学

Nature Reviews Cardiology Pub Date : 2026-09-02 DOI: 10.1038/s41569-026-01339-y

Cong Luo, Tao Li, Jihoon Tak, Matthew DeBerge, Kuang-Lei Tsai, Holger K Eltzschig

{"title":"The role of hypoxia-inducible factors in myocardial ischaemia-reperfusion injury and cardioprotection.","authors":"Cong Luo, Tao Li, Jihoon Tak, Matthew DeBerge, Kuang-Lei Tsai, Holger K Eltzschig","doi":"10.1038/s41569-026-01339-y","DOIUrl":"https://doi.org/10.1038/s41569-026-01339-y","url":null,"abstract":"In the setting of myocardial ischaemia-reperfusion injury, ischaemia induces severe myocardial hypoxia, whereas the abrupt reintroduction of oxygen during reperfusion further amplifies tissue injury through redox imbalance. This dynamic stabilizes hypoxia-inducible factors (HIFs), which become transcriptionally active and induce hypoxia-responsive gene networks. In turn, HIF-dependent programmes orchestrate adaptive responses to acute hypoxia, including metabolic reprogramming towards glycolysis, promotion of extracellular adenosine signalling, induction of epidermal growth factor pathways and integration with circadian regulatory circuits. Collectively, these programmes increase myocardial resistance to ischaemic stress and limit ischaemia-reperfusion injury. In this Review, we examine the functional roles of HIFs in cardioprotection, with a particular focus on their contributions to ischaemic preconditioning or remote preconditioning and the HIF-dependent pathways that drive these cardioprotective effects. Given that pharmacological HIF stabilizers are already in clinical use for the treatment of renal anaemia, these insights provide a clear translational framework, positioning HIF activation as a plausible and immediately actionable therapeutic approach to prevent or treat myocardial ischaemia-reperfusion injury.","PeriodicalId":18976,"journal":{"name":"Nature Reviews Cardiology","volume":" ","pages":""},"PeriodicalIF":50.2,"publicationDate":"2026-09-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148881303","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Intracoronary imaging in percutaneous coronary intervention: why, when, how and which from large, randomized trials. 经皮冠状动脉介入治疗中的冠状动脉内显像：为什么，何时，如何以及从大型随机试验中选择。

IF 50.2 1区医学

Nature Reviews Cardiology Pub Date : 2026-09-02 DOI: 10.1038/s41569-026-01342-3

Flavio Giuseppe Biccirè, Nieves Gonzalo, Joo-Yong Hahn, Ik-Kyung Jang, Lorenz Räber

{"title":"Intracoronary imaging in percutaneous coronary intervention: why, when, how and which from large, randomized trials.","authors":"Flavio Giuseppe Biccirè, Nieves Gonzalo, Joo-Yong Hahn, Ik-Kyung Jang, Lorenz Räber","doi":"10.1038/s41569-026-01342-3","DOIUrl":"10.1038/s41569-026-01342-3","url":null,"abstract":"The introduction of intracoronary imaging (ICI) into clinical practice has been one of the major advances in percutaneous coronary intervention (PCI) for patients with atherosclerotic coronary artery disease. However, because the procedural advantages of ICI in routine clinical practice can be offset by higher costs and longer procedural times, high-quality evidence demonstrating the net clinical benefits of ICI guidance has long been awaited. The publication of eight large (n > 1,000 patients), international, randomized studies (the ILUMIEN IV, IVUS-ACS, IVUS-CHIP, IVUS-XPL, OCCUPI, OCTOBER, RENOVATE-COMPLEX-PCI and ULTIMATE trials) has provided substantial data on the clinical use of ICI guidance to improve the safety and outcomes of patients undergoing PCI. However, the heterogeneity of the study populations, lack of standardized criteria across ICI protocols and the mixed results of randomized trials have left uncertainty about why and when the use of ICI confers a benefit in real-world settings. In this Review, by discussing the study characteristics and procedural aspects that contributed to the consistency and heterogeneity across trials, we provide a practical and comprehensive appraisal of the appropriateness - why, when, how and which - of ICI guidance in the clinical decision-making process for contemporary PCI, with the overall aim of improving clinical outcomes.","PeriodicalId":18976,"journal":{"name":"Nature Reviews Cardiology","volume":" ","pages":""},"PeriodicalIF":50.2,"publicationDate":"2026-09-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148881319","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Langendorff-free dissociation of adult mouse hearts. 成年小鼠心脏Langendorff-free解离。

IF 50.2 1区医学

Nature Reviews Cardiology Pub Date : 2026-09-02 DOI: 10.1038/s41569-026-01346-z

Matthew Ackers-Johnson, Davor Pavlovic

引用次数: 0

Identifying the coronary metabolic dilator. 鉴定冠状动脉代谢扩张剂。

IF 50.2 1区医学

Nature Reviews Cardiology Pub Date : 2026-09-01 DOI: 10.1038/s41569-026-01345-0

Adam G Goodwill

引用次数: 0

Dyslipidaemia and hepatic steatosis: mechanisms and implications for lipid-lowering therapy. 血脂异常和肝脂肪变性：降脂治疗的机制和意义。

IF 50.2 1区医学

Nature Reviews Cardiology Pub Date : 2026-08-27 DOI: 10.1038/s41569-026-01336-1

Maurizio Averna, M Mahmood Hussain, Giuseppe Danilo Norata

{"title":"Dyslipidaemia and hepatic steatosis: mechanisms and implications for lipid-lowering therapy.","authors":"Maurizio Averna, M Mahmood Hussain, Giuseppe Danilo Norata","doi":"10.1038/s41569-026-01336-1","DOIUrl":"https://doi.org/10.1038/s41569-026-01336-1","url":null,"abstract":"Dyslipidaemia and hepatic steatosis are interconnected metabolic disorders, often associated with obesity and diabetes mellitus, that contribute to the burden of cardiovascular disease. Hepatic steatosis is now recognized as a specific subset of metabolic dysfunction-associated steatotic liver disease (MASLD). Several processes contribute to lipid deposition in the liver, including increased de novo lipogenesis, impaired fatty acid oxidation and reduced lipoprotein biosynthesis. Hepatic lipid accumulation can also result from lipid-lowering therapies that impair lipoprotein production, thus requiring careful monitoring of hepatic lipid content in patients taking these medications. By contrast, drugs that lower plasma levels of lipids by increasing hepatic expression of the LDL receptor do not lead to lipid accumulation in the liver; however, some patients are less responsive than others to these therapies. Therefore, new therapeutics that decrease lipoprotein production without causing steatosis are needed. Indeed, balanced modulation of hepatic lipoprotein production and secretion, as well as systemic and cellular lipid catabolism, is crucial for hepatic lipid homeostasis. Strategies that target both plasma and hepatic lipid levels will help to reduce the burden of atherosclerosis and MASLD. In this Review, we discuss mechanistic links between dyslipidaemia and hepatic steatosis, emphasizing lipid-lowering therapies and their effects on hepatic lipid accumulation.","PeriodicalId":18976,"journal":{"name":"Nature Reviews Cardiology","volume":" ","pages":""},"PeriodicalIF":50.2,"publicationDate":"2026-08-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148840790","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Bedside epicardial adipose tissue assessment in the era of advanced adipose phenotyping. 晚期脂肪表型时代的床边心外膜脂肪组织评估。

IF 50.2 1区医学

Nature Reviews Cardiology Pub Date : 2026-08-27 DOI: 10.1038/s41569-026-01344-1

Dafni Charisopoulou, George Koulaouzidis

引用次数: 0

Reply to 'Bedside epicardial adipose tissue assessment in the era of advanced adipose phenotyping'. 回复“晚期脂肪表型时代的床边心外膜脂肪组织评估”。

IF 50.2 1区医学

Nature Reviews Cardiology Pub Date : 2026-08-27 DOI: 10.1038/s41569-026-01343-2

Shaun Khanna, Nitesh Nerlekar

引用次数: 0

Nicotine-containing products and the cardiovascular system: mechanisms and global health implications. 含尼古丁产品和心血管系统：机制和全球健康影响。

IF 50.2 1区医学

Nature Reviews Cardiology Pub Date : 2026-08-20 DOI: 10.1038/s41569-026-01331-6

Thomas Münzel, Marin Kuntic, John F Keaney, Julia Lurz, Filippo Crea, Thomas F Lüscher, Sanjay Rajagopalan, Andreas Daiber

{"title":"Nicotine-containing products and the cardiovascular system: mechanisms and global health implications.","authors":"Thomas Münzel, Marin Kuntic, John F Keaney, Julia Lurz, Filippo Crea, Thomas F Lüscher, Sanjay Rajagopalan, Andreas Daiber","doi":"10.1038/s41569-026-01331-6","DOIUrl":"https://doi.org/10.1038/s41569-026-01331-6","url":null,"abstract":"Tobacco use and emerging nicotine-delivery systems remain major, preventable drivers of cardiovascular disease worldwide. Although tobacco cigarette smoking has declined in some high-income regions, progress is uneven, with persistently high rates across parts of Europe, alongside rapidly expanding global markets for e-cigarettes, heated-tobacco products and oral nicotine formulations. Youth addiction to nicotine-containing products has emerged as an urgent public health challenge, as engineered e-cigarette devices delivering large nicotine doses facilitate early dependence and might establish lifelong exposure trajectories. Regulatory frameworks have not kept pace with this innovation, allowing new platforms to enter markets faster than safety evidence can mature. Leading cardiovascular societies and regulatory authorities agree that no nicotine-containing product can be safe for the cardiovascular system. Nicotine promotes sympathetic activation, haemodynamic stress, oxidative imbalance and inflammation, and endothelial nitric oxide synthase uncoupling and dysfunction, contributing to atherosclerotic plaque instability in animal models and humans. Studies in humans demonstrate adverse vascular responses across all nicotine-containing products, although interpreting studies requires caution and long-term outcome data are lacking. In this Review, we integrate mechanistic, biomarker, preclinical and clinical data to define a cardiovascular continuum of harm from nicotine-containing products, in which eliminating combustion reduces but does not eliminate vascular toxicity.","PeriodicalId":18976,"journal":{"name":"Nature Reviews Cardiology","volume":" ","pages":""},"PeriodicalIF":50.2,"publicationDate":"2026-08-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148795915","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Cardiovascular research in China: pathways, incentives and editorial implications. 中国心血管研究：途径、激励和编辑意义。

IF 50.2 1区医学

Nature Reviews Cardiology Pub Date : 2026-08-19 DOI: 10.1038/s41569-026-01341-4

Chengming Fan

引用次数: 0